BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 28.04.1998

Guidance for Industry on PAC-ATLS: Postapproval Changes Analytical Testing Laboratory Sites; Availability

The Food and Drug Administration (FDA) is announcing the availability of a guidance for industry entitled ``PAC-ATLS: Postapproval Changes--Analytical Testing Laboratory Sites.'' This guidance provides recommendations to pharmaceutical sponsors of new drug applications (NDA's) and abbreviated new drug applications (ANDA's) who intend to change an analytical testing laboratory site for components, drug product containers, closures, packaging materials, in- process materials, or drug products during the postapproval period. This guidance is intended to ease the burden of notification, under certain circumstances, for analytical testing laboratory site changes currently requiring prior approval supplements under the human drug regulations.

Source: Federal Register — Food and Drug AdministrationOpen original release →